Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)

Bimekizumab treatment led to superior improvements in joint and skin efficacy outcomes
at week 16 compared with placebo in patients with psoriatic arthritis and inadequate
response or intolerance to TNFα inhibitors. The safety profile of bimekizumab was
consistent with previous phase 3 studies in patients with plaque psoriasis, and studies
of IL-17A inhibitors.

Related Keywords

Helsinki ,Eteläuomen Läi ,Finland ,Germany ,Australia ,Japan ,United States ,Hungary ,United Kingdom ,Italy ,Czech Republic ,Canada ,Russia ,Poland ,America , ,Health Assessment Questionnaire ,Health Survey ,International Conference ,Harmonisation Guidance ,Good Clinical ,Classification Criteria ,Psoriatic Arthritis ,North America ,Health Assessment Questionnaire Disability Index ,Psoriasis Area ,Severity Index ,Physical Component Summary ,Patient Global Assessment ,Investigator Global Assessment ,Nail Psoriasis Severity Index ,Psoriatic Arthritis Impact ,Arthritis Pain ,Functional Assessment ,Chronic Illness Therapy Fatigue ,Query Advisor ,